Characteristics of prostate cancers detected at low PSA levels
- 30 October 2003
- journal article
- Published by Wiley in The Prostate
- Vol. 58 (3) , 232-237
- https://doi.org/10.1002/pros.10325
Abstract
BACKGROUND When age‐referenced PSA levels as recommended by Oesterling et al. 1 were used as a biopsy criterion, only 25% of the cancers detected in a population based PSA Screening Project were organ‐confined. This observation led to the decision to use low PSA levels as the sole indication for biopsy. Since 1995 age‐referenced PSA levels of 1.25–3.25 ng/ml have been used in combination with a percentage free PSA cutoff of 18%. This PSA cutoff reduction led to a statistically significant migration to lower pathological stages with a decreased prostate cancer mortality in the years 1996–2001. However, concerns have been raised that screening with low PSA levels may detect clinically insignificant cancers. MATERIALS AND METHODS We evaluated prostate cancer patients with low PSA levels in terms of heterogeneity, clinical significance, multifocality, and tumor biology including ploidy and proliferation index. RESULTS Concerning heterogeneity the Gleason score of the needle biopsy failed to predict the Gleason score of the radical prostatectomy specimen in nearly 40% of prostate cancer patients; regarding multifocality 65% of patients with low PSA levels showed multifocal lesions and 36% exhibited tetraploid DNA distribution; more than 50% of tetraploid tumors were found in patients with tumor volumes of less than 0.5 cm3. Ploidy correlated with the Ki‐67 proliferation index, but not with tumor volume. CONCLUSIONS These results demonstrate that small prostate cancers with low PSA levels and low tumor volumes exhibit all features of prostate cancers with higher tumor volumes and show the characteristics of malignant cancers, i.e., multifocality, tetraploidy, and high proliferative activity.Keywords
This publication has 30 references indexed in Scilit:
- Pathological features of prostate cancer detected on initial and repeat prostate biopsy: Results of the prospective European prostate cancer detection studyThe Prostate, 2001
- Microfocal prostate cancer: biopsy cancer volume does not predict actual tumour volumeBritish Journal of Urology, 1998
- Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancerSurgery, 1996
- The Volume of Prostate Cancer in the Biopsy Specimen Cannot Reliably Predict the Quantity of Cancer in the Radical Prostatectomy Specimen on an Individual BasisJournal of Urology, 1995
- Original Articles: Prostate Cancer: Pathological Features of Hereditary Prostate CancerJournal of Urology, 1995
- Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki‐67 and PCNA expressionThe Prostate, 1995
- Evaluation of Ki‐67 Monoclonal Antibody as Prognostic Indicator for Prostatic CarcinomaBritish Journal of Urology, 1993
- Pathological and clinical associations of Ki‐67 defined growth fractions in human prostatic carcinomaThe Prostate, 1992
- Growth fractions in human prostatic carcinoma determined by Ki‐67 immunostainingThe Journal of Pathology, 1988
- The value of perineal punch biopsy in estimating the histological grade of carcinoma of the prostateThe Prostate, 1980